Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
Journal:
MicroRNA
Volume:
5
Page:
222-229
Author(s):
Jingmei Lin, Xinjun Zhang, Zijin Zhao, Noah C. Welker, Yong Li, Yunlong Liu and Mary P. Bronner
Differential Expression of miR-31 between Inflammatory Bowel Disease and Microscopic Colitis
Journal:
MicroRNA
Volume:
3
Page:
155-159
Author(s):
Chen Zhang, Zijin Zhao, Hany Osman, Rao Watson, ILKe Nalbantoglu and Jingmei Lin
Current Concepts on the Genetics and Pharmacogenetics of Inflammatory Bowel Disease: Do they Help in Clinical Management?
Journal:
Current Genomics
Volume:
7
Page:
149-162
Author(s):
Peter Laszlo Lakatos and Laszlo Lakatos
New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
3505-3524
Author(s):
C. Alarcon de la Lastra, S. Sanchez-Fidalgo, I. Villegas and V. Motilva
Immune Abnormalities and Endotoxemia in Patients with Ulcerative Colitis and in Their First Degree Relatives: Attempts at Neutralizing Endotoxin- Mediated Effects
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
1937-1945
Author(s):
L. Amati, L. Caradonna, G. Leandro, T. Magrone, M. Minenna, G. Faleo, N. M. Pellegrino, E. Jirillo and D. Caccavo
Probiotic Lactobacilli: A New Perspective for the Treatment of Inflammatory Bowel Disease
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
1973-1980
Author(s):
Giuseppe Famularo, Luciana Mosca, Giovanni Minisola, Vito Trinchieri and Claudio De Simone1
Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer
Journal:
Current Drug Targets
Volume:
9
Page:
369-374
Author(s):
R. Atreya and M. F. Neurath
The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease
Journal:
Current Pharmaceutical Design
Volume:
15
Page:
2074-2086
Author(s):
Osamu Kanauchi, Keiichi Mitsuyama and Akira Andoh
Cytokines, Inflammation and Colon Cancer
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
451-464
Author(s):
L. Klampfer
Potassium Channel Openers and Improvement of Toxic Stress: Do they have Role in the Management of Inflammatory Bowel Disease?
Journal:
Inflammation & Allergy - Drug Targets (Discontinued)
Volume:
7
Page:
129-135
Author(s):
Azadeh Hosseini-Tabatabaei and Mohammad Abdollahi